<DOC>
	<DOCNO>NCT01992809</DOCNO>
	<brief_summary>Nonalcoholic fatty liver disease ( NAFLD ) clinical pathological condition , whose spectrum range steatosis steatohepatitis cirrhosis , patient without history alcohol abuse . Nonalcoholic steatohepatitis ( NASH ) , severe form ( NAFLD ) , emerge clinically important type chronic liver disease industrialized country characterize pathologically hepatocellular ballooning , Mallory 's hyaline , scatter inflammation perisinusoidal fibrosis . NASH associate cirrhosis decompensate subacute liver failure , progress hepatocellular cancer reoccur post transplantation.In absence establish treatment , therapy generally direct treatment risk factor metabolic syndrome . Recently , study demonstrate Polyunsaturated fatty acid ( PUFAs ) , omega3 type , could reduce TNFalfa , IL6 , aminotransferases , insulin resistance steatosis verify ultrasound . Neverthless , first study evaluate liver histology six month PUFA ( omega3 ) treatment patient NASH .</brief_summary>
	<brief_title>Omega 3 Supplementation Fatty Liver</brief_title>
	<detailed_description>Nonalcoholic fatty liver disease ( NAFLD ) clinical pathological condition , whose spectrum range steatosis steatohepatitis cirrhosis , patient without history alcohol abuse . Nonalcoholic steatohepatitis ( NASH ) , severe form ( NAFLD ) , emerge clinically important type chronic liver disease industrialized country characterize pathologically hepatocellular ballooning , Mallory 's hyaline , scatter inflammation perisinusoidal fibrosis . NASH associate cirrhosis decompensate subacute liver failure , progress hepatocellular cancer reoccur post transplantation . The 'two-hit ' hypothesis propose explain pathogenesis NASH , initial metabolic disturbance ( insulin resistance ) cause steatosis second pathogenic stimulus promote oxidative stress , increase generation reactive oxygen specie ( ROS ) , lipid peroxidation , resultant NASH . Insulin resistance play major role hepatic fat accumulation increase influx free fatty acid ( FFA ) peripheral fat store due enhance lipolysis , increase de novo hepatocyte triglyceride synthesis glucose reduce apo B production , diminishes fat export liver . In absence establish treatment , therapy generally direct treatment risk factor metabolic syndrome . Recently , study demonstrate Polyunsaturated fatty acid ( PUFAs ) , omega3 type , could reduce TNFalfa , IL6 , aminotransferases , insulin resistance steatosis verify ultrasound . Nevertheless , first study evaluate liver histology six month PUFA ( omega3 ) treatment patient NASH . Based aspect , aim prospective investigation , evaluate effectiveness PUFA ( omega3 ) treatment patient NASH . METHODS Population This study develop center study DHGNA/NASH Central Institute Hospital Clinics São Paulo , Brazil . This study comprise 60 patient diagnose NASH base liver biopsy finding . In addition , patient elevate alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) level least two occasion 6 month prior enrollment . Other cause liver disease include hepatobiliary system ultrasound , viral serology , autoantibody titer , serum iron , ferritin transferrin saturation , ceruloplasmin copper level alpha1-antitrypsin exclude . Patients &gt; 100 g/week alcohol intake determine detailed personal history , question family member , investigation previous medical record , exclude . Patients steatohepatitis accompany liver disease , systemic disease obesity , hyperlipidemia , diabetes intake hepatotoxic drug lipid-lowering agent exclude . Specific inform consent obtain study protocol approve Internal Review Board University São Paulo . Diagnosis diabetes type II , hypertension , dyslipidemia base criterion American Diabetes Association ( fast glucose 100mg/dl ; Triglyceride &gt; 150mg/dl ; HDL &lt; 40mg/dl man &lt; 50mg/dl woman ; &gt; 130mmHg systolic &gt; 85mmHg diastolic ) 28 . Overweight correspond body mass index ( BMI ) ≥ 25 kg/m2 obesity BMI ≥ 30 kg/m2 . Study Design Randomized , double blind , placebo control . Patients randomize two group : Group I / control : 30 NASH patient receive placebo orally 6 month Group II / ( PUFA- ( omega3 ) : 30 NASH patient receive PUFA- ( omega3 ) orally 6 month Laboratorial Assays ( every 2 month ) - AST , ALT , FA , GGT , BT/D/I , albumine , INR , plaquettes , Fe , fast glucose insulin , , peptide C , leptin , Total cholesterol , HDL . LDL , Triglycerides , - TNFalfa , IL6 , adiponectin , lipidic leuckocyte profile , EPA ( eicosapentaenoic acid ) , DHA ( docosahexaenoic ) Histological diagnosis Liver tissue fix 4 % formaldehyde process hematoxylin-eosin ( HE ) Masson Trichrome stain histological analysis . All specimen score single liver pathologist expertise NAFLD : macro- microvascular fatty change , zonal distribution , foci necrosis , portal perivenular fibrosis , inflammatory fibrotic infiltrate zonal distribution . The specimen blindly score accord NASH Activity Score ( NAS ) devise Pathology Committee NASH Clinical Research Network 29 . According NAS , score parameter include macro- microvascular fatty change , zonal distribution , foci necrosis , portal perivenular fibrosis , inflammatory fibrotic infiltrate zonal distribution .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Mineral Oil</mesh_term>
	<criteria>1870 year age , sex With without noninsulindependent diabetes glucose intolerance Absence alcoholism &lt; 20g ( woman ) &lt; 40g ( men ) ethanol/day , drug , schistosomiasis , hepatitis B C chronic liver disease cause determine Absence autoantibody rate copper ceruloplasmin normal Biopsyliver 12 month previous , show steatosis , lobular inflammatory infiltrate ballooning hepatocytes , may present Mallory 's corpuscle liver fibrosis stage I II , NAS score &gt; 5 ; Patients agree participate study sign informed consent . Poisoning exogenous oxidant Pregnancy lactation Prothrombin time &lt; 70 % platelet count &lt; 70 000/mm3 , bleed disorder , include alteration bleeding time Refusal cooperate research steatosis without sign inflammation balloon cirrhosis ( stage IV ) diabetes mellitus use insulin allergy fish flaxseed antiinflammatory use nonhormonal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Nonalcoholic fatty liver</keyword>
	<keyword>omega 3</keyword>
</DOC>